This is the first FDA-approved antimicrobial catheter lock solution. The FDA has approved taurolidine plus heparin (DefenCath®) catheter lock solution to reduce catheter-related bloodstream infections ...
BERKELEY HEIGHTS, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)--CorMedix Inc. (NYSE MKT: CRMD) today announced that it has received CE Mark approval for Neutrolin®, a catheter lock solution, for patients with central venous ...
Please provide your email address to receive an email when new articles are posted on . BOSTON — Neutrolin, an investigational new drug containing taurolidine, was shown to reduce catheter-related ...
Several randomized clinical trials with short-term follow-up have shown that patients on hemodialysis with prophylactic antibiotic catheter locks have reduced catheter-related bacteremia. However, the ...
The Food and Drug Administration (FDA) has approved DefenCath ® (taurolidine and heparin) catheter lock solution to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results